empty

NICE

28 results found for: NICE

NICE: Many chronic pain meds do more harm than good

Several commonly used treatments for chronic primary pain have little or no evidence that they work and shouldn’t be prescribed, NICE says in new draft guidance

NICE recommends steam treatment for enlarged prostate

Rezum recommended as a treatment option for moderate to severe lower urinary tract symptoms.

‘Lack of evidence’ for ibuprofen Covid-19 harm

The Commission on Human Medicines has said patients can take paracetamol or ibuprofen when self-medicating for symptoms of Covid-19.

NICE approves first anti-CRGP preparation for migraine

Fremanezumab now available on the NHS in England and Wales for up to 10,000 people.

Digital interventions can play a role says NICE

Digital tools should be offered in addition to existing health services, not as a replacement, says NICE

NICE calls for greater use of community pharmacies

NICE is calling for the NHS to make greater use of community pharmacies to promote health and wellbeing in local areas.

NICE fast-tracks epilepsy recommendation

Doctors can prescribe Epidyolex with clobazam, a seizure-preventing cannabis-based treatment.

European authorities approve cannabis-based medicine for epilepsy

European authorities have for the first time approved a cannabis-based medicine for use in severe childhood epilepsy.

NICE approves cluster headaches device

A handheld device that delivers a small electric current has been recommended in draft guidance by NICE.

New NICE guidelines on hypertension treatment

The new recommendations reduce the CVD risk threshold at which treatment for hypertension should be considered.

NICE chief executive to stand down

Sir Andrew Dillon has announced his intention to stand down as chief executive at the National Institute for Health and Care Excellence (NICE).

‘Not enough evidence’ to recommend cannabis says NICE

NICE has decided not to recommend the use of cannabis-based medicines in severe treatment-resistant epilepsy.

Integrate pharmacists into diabetes care, says RPS

Pharmacists in all settings should be integrated into services aimed at preventing and managing type 2 diabetes.

Glaucoma: A clear role for pharmacy

Recent studies suggest that community pharmacists should be part of glaucoma management pathways 

NICE goes green on asthma inhalers

Metered dose inhalers, containing hydrofluorocarbons, have estimated carbon footprints of 500g CO2eq per dose, compared to 20g in dry powder inhalers

Making headway: A pharmacist's guide to headaches

Headache is the umbrella term used for a number of different conditions that can be difficult for pharmacists to differentiate and therefore manage appropriately

Scenario: Vitamin D supplements

Customer Nusrat Begum is talking to pharmacist Parveen about how the vitamin D supplement she is taking doesn’t seem to be working...

Industry & govt near agreement on PPRS successor

The NHS across the UK is expected to save around £930m on its medicine bill under a new scheme

NICE backs pharmacy

NICE says community pharmacy needs embedding in NHS pathways – something the sector has been saying for years...

NICE touch – but will NHS England listen?

Will the recent NICE guidance, which focuses on how community pharmacies can help maintain and improve people’s physical and mental health, also focus the minds of NHS England and Public Health England? Mike Holden from Pharmacy Complete hopes so

Previous 1 2 Next


This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.